NorthSea Therapeutics

Investment area

Seed Investments



Date of investment

November 2017

NorthSea Therapeutics is developing icosabutate a first-in-class Structurally Engineered Fatty Acid (SEFA) for Non-Alcoholic SteatoHepatitis or NASH. In addition, NorthSea is evaluating the potential of various SEFAs in other metabolic, inflammatory and fibrotic diseases.

Visit site


Søren Møller

Managing Partner

Departments: Life Sciences Operating Committee, Seed Investments

Søren joined Novo A/S in 2011 as Managing Investment Director of Seed Investments.

Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine.

Prior to joining Seed Investments, Søren served as global manager of Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S. During Søren’s tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk.

Søren serves on the Board of Directors of EpiTherapeutics (sold to Gilead), AMRA, Biosyntia, Reapplix and Northsea Therapeutics. Since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark) and DVCA (Danish Venture Capital Association).